SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

Core Insights - SI-BONE, Inc. reported strong financial results for Q1 2025, with significant revenue growth and improved profitability metrics [3][4][7]. Financial Performance - Worldwide revenue reached $47.3 million, a 24.9$37.9 million in Q1 2024 [4][9]. - U.S. revenue was $44.8 million, reflecting a 26.6$35.4 million in the same period last year [4][9]. - Gross profit was $37.7 million, up 26.2$29.9 million in Q1 2024, with a gross margin of 79.7%, an improvement of 80 basis points [5][9]. - Operating expenses increased by 7.8% to 45.2 million, driven by higher commercial activity and R&D investments [6][9]. - Operating loss improved by 37.9% to 7.5 million, while net loss decreased by 40.0% to $6.5 million, or$0.15 per diluted share [7][9]. - Adjusted EBITDA was positive at $0.5 million, a significant improvement from an adjusted EBITDA loss of$4.0 million in Q1 2024 [8][9]. Operational Highlights - The company added over 300 active U.S. physicians in the quarter, totaling over 1,400, representing a 27.3% growth [9]. - The strong underlying procedure demand and the rollout of new products contributed to revenue growth [4][9]. Guidance and Outlook - SI-BONE updated its 2025 revenue guidance to a range of $193.5 million to$197.5 million, implying year-over-year growth of approximately 16% to 18% [10][11]. - The company expects a gross margin of 78% for the full year and anticipates operating expenses to grow at around 10% [10][11].